ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Health Technology

Trans Genic Inc.

Business Summary

Trans Genic Inc. engages in the development, distribution, and licensing of genetically engineered animals and antibodies. It operates through the following segments: Contract Research Organization (CRO), Diagnostic Analysis, and Trans Genic Business Service (TGBS). The CRO segment deals with clinical trials, pharmacological tests, pharmacokinetic tests, non-clinical trials, and the production of genetically modified mice. The Diagnostic Analysis segment provides pathological diagnosis, gene analysis, and drug discovery support services for personalized medicine. The TGBS segment offers advice and support services related to the promotion of new business through mergers and acquisitions, business succession, and business revitalization. The company was founded on April 21, 1998 and is headquartered in Kumamoto, Japan.

Financial Highlights

Mar 2020 JPYUSD
Revenue11,046.67M101.60M
Gross Profit1,779.72M16.36M
Operating income62.70M0.57M
Income before tax-249.65M-2.29M
Net income-440.71M-4.05M
EBITDA292.68M2.69M
Diluted EPS-25.37-0.23
Dividends Per Share00
Total Assets7,571.68M70.13M
Total liabilities3,154.97M29.22M
Total equity4,416.61M40.91M
Operating cash flow-20.98M-0.19M
Currency in JPYCurrency in USD

Historical Data

 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 2,290.28M 2,302.90M 3,601.28M 8,674.50M 11,046.67M
Gross Profit 672.62M 748.93M 822.45M 1,498.44M 1,779.72M
Operating income 50.41M 153.94M 60.55M 270.06M 62.70M
Income before tax 18.95M 81.93M 14.45M 202.87M -249.65M
Net income 14.58M 80.69M 20.89M 202.21M -440.71M
EBITDA 153.96M 266.39M 204.45M 460.51M 292.68M
Diluted EPS 1.05 5.62 1.39 11.90 -25.37
Dividends Per Share 0 0 0 0 0
Total Assets 3,905.44M 3,902.42M 5,934.68M 6,475.27M 7,571.68M
Total liabilities 835.66M 729.09M 1,592.85M 1,588.53M 3,154.97M
Total equity 3,069.78M 3,173.32M 4,341.82M 4,886.74M 4,416.61M
Operating cash flow 214.36M 232.81M 219.05M 147.69M -20.98M
 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 19.07M 21.26M 32.49M 78.22M 101.60M
Gross Profit 5.60M 6.91M 7.42M 13.51M 16.36M
Operating income 0.41M 1.42M 0.54M 2.43M 0.57M
Income before tax 0.15M 0.75M 0.13M 1.82M -2.29M
Net income 0.12M 0.74M 0.18M 1.82M -4.05M
EBITDA 1.28M 2.46M 1.84M 4.15M 2.69M
Diluted EPS 0.00 0.05 0.01 0.10 -0.23
Dividends Per Share 0 0 0 0 0
Total Assets 34.74M 35.02M 55.80M 58.50M 70.13M
Total liabilities 7.43M 6.54M 14.97M 14.35M 29.22M
Total equity 27.31M 28.47M 40.82M 44.15M 40.91M
Operating cash flow 1.78M 2.14M 1.97M 1.33M -0.19M

Valuation Measures

Mar 2020
PER--
ROA-6.27%
ROE-9.47%
Operating margin0.56%
Profit margin-3.98%

Key executives

  • President, CEO & Representative Director: Kenji Fukunaga
  • Director, Manager-Finance & Accounting: Kazuo Watanabe
  • Director & Chief Technology Officer: Kenichi Yamamura
  • Director, Manager-Personnel & General Affairs: Yutaka Funabashi
  • Director & GM-Contract Research Organization: Shunichi Kitajima

Shareholders

  • Mutoh Co., Ltd. (0.9%)
  • FUKUNAGA KENJI /TRANS GENIC/ (0.6%)
  • HARADA IKUO (0.6%)
  • MIZUKOSHI ATSUSHI (0.5%)
  • Limousine International KK (0.5%)
  • SHIMADA NORIYASU (0.5%)
  • SASAKI NORITAKA /ITABASHI/ (0.4%)
  • Siemens Fonds Invest GmbH (0.2%)
  • FUNABASHI YUTAKA (0.1%)
  • Trans Genic Inc. (0.0%)

Contact Details

Related Companies

  • Galax Corp.
  • TG Business Service Inc.
  • GeneticLab Co., Ltd.
  • New Drug Research Center Inc.
  • GP Biosciences Ltd. /Genetic Analysis Business/
  • Primmune Inc

Competitors

    Last Updated on 25 Sep, 2020

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

    Stay ahead with our exclusives on Asia;
    the most dynamic market in the world.

    Stay ahead with our exclusives on Asia

    Get trusted insights from experts within Asia itself.

    Get trusted insights from experts
    within Asia itself.

    Try 1 month for $0.99

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

    This is your last free article this month

    Stay ahead with our exclusives on Asia; the most
    dynamic market in the world
    .

    Get trusted insights from experts
    within Asia itself.

    Try 3 months for $9

    Offer ends July 31st

    Your trial period has expired

    You need a subscription to...

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers and subscribe

    Your full access to the Nikkei Asian Review has expired

    You need a subscription to:

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers
    NAR on print phone, device, and tablet media